Brokerages expect The Medicines Company (NASDAQ:MDCO) to announce earnings of ($0.77) per share for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for The Medicines’ earnings. The highest EPS estimate is ($0.63) and the lowest is ($1.02). The Medicines reported earnings per share of ($1.44) in the same quarter last year, which would suggest a positive year over year growth rate of 46.5%. The company is scheduled to issue its next quarterly earnings results on Wednesday, April 25th.
According to Zacks, analysts expect that The Medicines will report full year earnings of ($2.71) per share for the current fiscal year, with EPS estimates ranging from ($3.45) to ($2.10). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.02) per share, with EPS estimates ranging from ($2.33) to ($1.53). Zacks’ EPS averages are a mean average based on a survey of research firms that cover The Medicines.
The Medicines (NASDAQ:MDCO) last issued its quarterly earnings data on Wednesday, February 21st. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.48) by ($0.71). The company had revenue of $8.60 million for the quarter, compared to analysts’ expectations of $20.71 million. The Medicines had a negative net margin of 1,035.27% and a negative return on equity of 316.40%. The firm’s revenue for the quarter was down 50.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.19) earnings per share.
MDCO has been the topic of a number of research analyst reports. Zacks Investment Research downgraded shares of The Medicines from a “hold” rating to a “sell” rating in a research report on Tuesday, December 26th. ValuEngine raised shares of The Medicines from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Oppenheimer set a $50.00 price objective on shares of The Medicines and gave the company a “buy” rating in a research report on Monday, January 15th. Citigroup raised shares of The Medicines from a “neutral” rating to a “buy” rating and set a $40.00 price objective on the stock in a research report on Monday, January 22nd. Finally, JPMorgan Chase reissued an “overweight” rating and set a $45.00 price objective on shares of The Medicines in a research report on Wednesday, January 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. The Medicines currently has a consensus rating of “Buy” and a consensus price target of $50.00.
The Medicines stock traded down $1.26 during mid-day trading on Friday, reaching $29.76. 988,616 shares of the company traded hands, compared to its average volume of 1,171,874. The company has a current ratio of 3.21, a quick ratio of 3.18 and a debt-to-equity ratio of 26.06. The company has a market cap of $2,180.93, a P/E ratio of -3.54 and a beta of 0.65. The Medicines has a 52-week low of $24.45 and a 52-week high of $55.95.
In other news, Director William Crouse sold 7,500 shares of the company’s stock in a transaction dated Wednesday, March 21st. The shares were sold at an average price of $32.26, for a total value of $241,950.00. Following the sale, the director now directly owns 60,633 shares of the company’s stock, valued at approximately $1,956,020.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 8.22% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in MDCO. Quantbot Technologies LP purchased a new stake in shares of The Medicines in the 3rd quarter worth about $171,000. SG Americas Securities LLC bought a new position in The Medicines in the 3rd quarter worth about $198,000. American International Group Inc. boosted its stake in The Medicines by 3.7% in the 3rd quarter. American International Group Inc. now owns 54,031 shares of the company’s stock worth $2,001,000 after purchasing an additional 1,947 shares in the last quarter. Trexquant Investment LP boosted its stake in The Medicines by 61.2% in the 3rd quarter. Trexquant Investment LP now owns 12,500 shares of the company’s stock worth $463,000 after purchasing an additional 4,747 shares in the last quarter. Finally, KBC Group NV boosted its stake in The Medicines by 1.6% in the 3rd quarter. KBC Group NV now owns 149,099 shares of the company’s stock worth $5,523,000 after purchasing an additional 2,347 shares in the last quarter.
WARNING: “-$0.77 Earnings Per Share Expected for The Medicines Company (MDCO) This Quarter” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/0-77-earnings-per-share-expected-for-the-medicines-company-mdco-this-quarter.html.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Get a free copy of the Zacks research report on The Medicines (MDCO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.